EMPACON L 25/5 TABLET

Product Description

EMPACON L 25/5 TABLETEmpagliflozin 25 mg + Linagliptin 5 mgProduct Description: EMPACON L 25/5 TABLET is an advanced oral antidiabetic combination formulated with Empagliflozin 25 mg and Linagliptin 5 mg, designed to deliver comprehensive glycemic control in adults with Type 2 Diabetes Mellitus. This dual-action DPP-4 inhibitor and SGLT2 inhibitor therapy enhances insulin function and promotes glucose excretion, supporting better metabolic outcomes.Key Benefits: Dual mechanism improves fasting and postprandial blood glucose levels Reduces HbA1c with minimal risk of hypoglycemia Supports cardiovascular and renal protection in diabetic patients Convenient once-daily dosing improves adherence Usage/Application: Indicated as an adjunct to diet and exercise for managing Type 2 diabetes, particularly in patients requiring a combination of SGLT2 and DPP-4 inhibitors. Widely used in diabetology, general medicine, and endocrinology practices.Composition: Empagliflozin 25 mg Linagliptin 5 mg Excipients q.s. Target Buyers: Ideal for pharma distributors, diabetic care retailers, hospital supply chains, and bulk buyers seeking high-efficacy antidiabetic formulations with consistent quality and regulatory compliance.Availability: Ready for bulk procurement, private labeling, and pharma distribution partnerships across India and export markets.